PWUP: PowerUp Acquisition Corp. Stock

by  •  • Comments Off on PWUP: PowerUp Acquisition Corp. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 100.55
Enterprise Value ($M) 100.56
Book Value ($M) -0.32
Book Value / Share -0.04
Price / Book -312.17
NCAV ($M) -20.22
NCAV / Share -2.25
Price / NCAV -4.97

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) 0.01
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 0.20
Current Ratio 0.20

Balance Sheet (mrq) ($M)
Current Assets 0.08
Assets 19.98
Liabilities 20.30
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -1.34
Net Income 4.46
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -0.65
Cash from Investing 284.92
Cash from Financing -284.76

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Glazer Capital, Llc 0.34 -98.63
02-13 13G/A Bank Of Nova Scotia 0.00 -100.00
02-07 13G/A Adage Capital Partners Gp, L.l.c. 0.00 -100.00
09-05 13D SRIRAMA Associates, LLC 48.00
08-28 13G/A PowerUp Sponsor LLC 31.90 -60.07

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-11 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA
2023-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPO
2023-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PU
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT P

(click for more detail)

Similar Companies
PAHC – Phibro Animal Health Corporation PROC – Procaps Group S.A.
PTGX – Protagonist Therapeutics, Inc. QTTB – Q32 Bio Inc.
RANI – Rani Therapeutics Holdings, Inc.


Financial data and stock pages provided by
Fintel.io